Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Novo Nordisk on Wednesday posted second-quarter sales broadly in line with expectations, after last week cutting its full-year guidance and announcing its new CEO.
Overall revenues rose 13% year-on-year at constant exchange rates to 76.86 billion Danish kroner ($11.92 billion) over the period, just ahead of the 76.6 billion Danishkroner forecast.
Quarterly net profit came in at 26.5 billion Danish kroner, versus 26.6 billion Danish kroner analysts expected.
This is a developing story. Please check back for updates.
About The Author
